View Filing Data

Print Document View Excel Document

Document And Entity Information - shares	6 Months Ended
Document And Entity Information - shares	Jun. 30, 2015	Aug. 12, 2015
Entity Registrant Name	RestorGenex Corp
Entity Central Index Key	0001053691
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		18,614,968
Document Type	10-Q
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q2
Amendment Flag	false

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
CURRENT ASSETS
Cash and cash equivalents	$ 16,472,761	$ 21,883,887
Prepaid expenses, deposits and other assets	1,357,191	2,286,930
	17,829,952	24,170,817
PROPERTY AND EQUIPMENT, NET	68,782	102,315
OTHER ASSETS
Intangible assets, net	6,449,628	6,449,628
Goodwill	12,055,991	12,055,991
Investment in Or-Genix	250,000
TOTAL ASSETS	36,654,353	42,778,751
CURRENT LIABILITIES
Accounts payable	337,589	417,307
Other accrued liabilities	2,230,251	1,921,293
	2,567,840	2,338,600
DEFERRED TAXES	2,274,526	2,274,526
TOTAL LIABILITIES	4,842,366	4,613,126
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY
Issued and outstanding; $0.001 par value; 1,000,000,000 shares authorized; 2015 - 18,614,968; 2014 - 18,614,968	18,615	18,615
Additional paid-in-capital	114,569,484	113,437,384
Accumulated deficit	(82,776,112)	(75,290,374)
Total stockholders' equity	31,811,987	38,165,625
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 36,654,353	$ 42,778,751

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares	Jun. 30, 2015	Dec. 31, 2014
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	1,000,000,000	1,000,000,000
Common stock, shares issued (in shares)	18,614,968	18,614,968
Common stock, shares outstanding (in shares)	18,614,968	18,614,968

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
EXPENSES
Research and development	$ 1,115,796	$ 266,906	$ 2,667,348	$ 436,238
General and administrative	1,881,278	1,210,832	3,842,378	2,221,690
Depreciation and amortization	6,198	323,741	12,482	515,071
Former employee severance expense	967,683		967,683
TOTAL EXPENSES	3,970,955	1,801,479	7,489,891	3,172,999
LOSS FROM OPERATIONS	(3,970,955)	(1,801,479)	(7,489,891)	(3,172,999)
OTHER (INCOME)/EXPENSES
Loss on settlement of notes payable - related parties		1,829,562		1,829,562
Loss on settlement of notes payable		876,543		876,543
Other (income) expenses	(1,633)	(2,466)	(4,153)	(446)
Interest expense		136,584		194,878
TOTAL OTHER (INCOME)/EXPENSES	(1,633)	2,840,223	(4,153)	2,900,537
LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	(3,969,322)	(4,641,702)	(7,485,738)	(6,073,536)
Benefit from income taxes		186,470		238,129
NET LOSS	$ (3,969,322)	$ (4,455,232)	$ (7,485,738)	$ (5,835,407)
TOTAL BASIC AND DILUTED NET LOSS PER SHARE (in dollars per share)	$ (0.21)	$ (0.35)	$ (0.40)	$ (0.62)
BASIC WEIGHTED AVERAGE SHARES OUTSTANDING (in shares)	18,614,968	12,867,845	18,614,968	9,483,395
FULLY-DILUTED WEIGHTED AVERAGE SHARES OUTSTANDING (in shares)	18,614,968	12,867,845	18,614,968	9,483,395

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
CASH FLOWS (USED IN) OPERATING ACTIVITIES
Net loss	$ (7,485,738)	$ (5,835,407)
Adjustments to reconcile net loss to net cash (used in) operating activities
Depreciation and amortization	12,482	515,071
Loss on disposal of fixed assets	49,278	6,056
Employee and director stock-based compensation - non-cash	1,132,616	291,200
Stock warrant expense - non-cash	261,570
Deferred income taxes		(238,129)
Loss on settlement of note payable - related parties		1,829,562
Loss on settlement of note payable		876,543
Changes in other assets and liabilities affecting cash flows used in operating activities
Prepaid expenses, deposits and other assets	667,653	461,933
Accounts payable and accrued liabilities	229,240	(3,027,926)
Net cash (used in) operating activities	(5,132,899)	(5,121,098)
CASH FLOWS (USED IN) INVESTING ACTIVITIES
Investment in Or-Genix	(250,000)
Purchase of fixed assets	(28,227)
Net cash (used in) investing activities	(278,227)
CASH FLOWS PROVIDED BY FINANCING ACTIVITIES
Proceeds on notes payable		400,000
Proceeds from issuance of common stock		31,605,727
Net cash provided by financing activities		32,005,727
NET (DECREASE) INCREASE CASH AND CASH EQUIVALENTS	(5,411,126)	26,884,629
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	21,883,887	254,964
CASH AND CASH EQUIVALENTS AT END OF PERIOD	16,472,761	27,139,593
NON-CASH INVESTING AND FINANCING ACTIVITIES
Acquisition of business in exchange for common stock		6,800,000
Conversion of accounts payable to notes payable related to Company's outside law firm		407,998
Issuance of shares of common stock and stock warrants as payment of notes payable - related parties		1,105,475
Issuance of shares of common stock and stock warrants as payment of notes payable		517,945
Issuance of shares of common stock and stock warrants as payment of accounts payable and accrued liabilities		$ 1,361,404

Note 1 - Description of Business

6 Months Ended

Jun. 30, 2015

Notes to Financial Statements

Nature of Operations [Text Block]

1.	Description of Business

RestorGenex Corporation (“Company”) is a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology. The Company’s lead product is a novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in pre-clinical development in oncology, specifically glioblastoma multiforme. The Company’s current pipeline also includes a “soft” anti-androgen compound for the treatment of acne vulgaris. The Company’s novel inhibition of the PI3K/Akt/mTOR pathway and unique targeting of the androgen receptor show promise in a number of additional diseases, which the Company is evaluating for the purpose of creating innovative therapies that are safe and effective treatments to satisfy unmet medical needs.

Note 2 - Basis of Presentation and Significant Accounting Policies

6 Months Ended

Jun. 30, 2015

Notes to Financial Statements

Basis of Presentation and Significant Accounting Policies [Text Block]

2.	Basis of Presentation and Significant Accounting Policies

Basis of Presentation

The unaudited financial statements presented in this report represent the consolidation of RestorGenex Corporation and its consolidated subsidiaries.

The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) applicable to interim financial statements. Accordingly, certain information related to significant accounting policies and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) have been condensed or omitted. These unaudited condensed consolidated financial statements reflect, in the opinion of management, all material adjustments (which include only normally recurring adjustments) necessary to fairly state, in all material respects, the Company’s financial position, results of operations and cash flows for the periods presented.

Operating results for interim periods are not necessarily indicative of the results that can be expected for any subsequent interim period or for a full year. These interim financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto included in its annual report on Form 10-K for the year ended December 31, 2014.

On June 18, 2015, the Company changed its state of incorporation from the State of Nevada to the State of Delaware.

Correction of Prior Period Misstatements

In the fourth quarter of 2014, the Company recorded certain adjustments for misstatements related to prior 2014 interim and prior annual periods that had been deemed immaterial. See Note 2 to the Company’s consolidated financial statements for the year ended December 31, 2014, included in the Company’s annual report on Form 10-K for the year ended December 31, 2014, for further information as to the nature of the adjustments recorded in the fourth quarter of 2014.

In the prior year presentation of research and development expenses for the three months ended June 30, 2014, the Company presented expenses of $403,413. Such amount included $169,332 of general and administrative expenses for the three month period ended June 30, 2014, which was included in research and development expenses in the period as a classification offset to the inclusion of $169,332 of research and development expenses in general and administrative expenses for the three month period ended March 31, 2014. The Company did not separately present research and development expenses in its condensed consolidated statements of operations for the three months ended March 31, 2014 as presented in the prior year. The inclusion of this $169,332 classification offset in the prior period presentation of research and development expenses for the three months ended June 30, 2014 was not appropriate, and represents an immaterial misstatement in the prior year. The prior year presentation of research and development expenses for the six month period ended June 30, 2014 was correct as presented. In the current period presentation of the condensed consolidated statements of operations for the three months ended June 30, 2014, this item has been corrected by decreasing research and development expenses and increasing general and administrative expenses by $169,332.

$2,706,105 of expense recognized in the three and six months ended June 30, 2014 condensed consolidated statements of operations from notes payable settlements was reclassified to “loss on settlement of notes payable – related parties” expenses for $1,829,562 and “loss on settlement of notes payable” expense for $876,543 in the current period condensed consolidated statements of operations presentation from “fair value of common stock exchanged for warrants and notes payable” expense in the prior period presentation. Furthermore, the presentation of these amounts in the current period presentation was moved to other expense from operating expenses reflecting the correction of an immaterial prior period misstatement related to the classification of losses on settlement of notes payable.

$186,470 and $238,129 of income tax benefit recognized in the three and six months ended June 30, 2014 was reclassified to benefit from income taxes in the current period condensed consolidated statements of operations from other (income) expense in the prior year presentation, representing the correction of a prior period immaterial misstatement related to the presentation of income tax benefit.

Reclassifications

Certain 2014 amounts were reclassified to conform to the manner of presentation in the current period. These reclassifications included:

$286,774 and $573,548 of amortization expense recognized in the three and six months ended June 30, 2014 condensed consolidated statements of operations from amortizing the prepaid expense asset for general financial advisory and investment banking services described in Note 4 to these condensed consolidated financial statements was reclassified to “general and administrative” expense in the current period condensed consolidated statements of operations presentation from “depreciation and amortization” expense where it was presented in the prior year. In the condensed consolidated statements of cash flows, the same amount was reclassified within the “cash flows used in operating activities” section from “depreciation and amortization” in the prior period presentation to “prepaid expenses, deposits and other assets” in the current period presentation.

$141,315 and $291,200 of expense recognized in the three and six months ended June 30, 2014 condensed consolidated statements of operations presentation from stock-based compensation and warrant expense described in Notes 9 and 10 to these condensed consolidated financial statements was reclassified to “general and administrative” ($108,490 and $258,375 for the three and six months ended June 30, 2014) and “research and development” ($32,825 for the three and six months ended June 30, 2014) in the current period condensed consolidated statements of operations presentation from “warrants, options and stock compensation” expense in the prior period presentation. In the condensed consolidated statements of cash flows, the same amount was reclassified within the “cash flows used in operating activities” section from “warrants, options and stock compensation” in the prior period presentation to “employee and director stock-based compensation – non-cash” in the amount of $291,200 in the current period presentation.

$384,604 and $516,290 of legal and professional services expense recognized in the three and six months ended June 30, 2014 condensed consolidated statements of operations was reclassified to “general and administrative” expense in the current period condensed consolidated statements of operations presentation from “legal and professional services” expense in the prior period presentation.

In the condensed consolidated statements of cash flows within net cash (used in) operating activities, $1,285,493 from loss on settlement of issuing shares for liabilities in the prior year presentation was reclassified to loss on settlement of note payable in the amount of $876,543 and accounts payable and accrued liabilities in the amount of $408,950 in the current year presentation.

Use of Estimates

The preparation of the Company’s condensed consolidated financial statements in accordance with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company’s condensed consolidated financial statements and accompanying notes. Although these estimates are based on the Company’s knowledge of current events and actions that the Company may undertake in the future, actual results may differ from such estimates and assumptions.

Income Taxes

The Company has no current tax provision due to its current and accumulated losses, which result in net operating loss carryforwards. The Company’s deferred tax liability relates to indefinite lived intangible assets. See Note 18 to the Company’s consolidated financial statements for the year ended December 31, 2014 included in the Company’s annual report on Form 10-K for the year ended December 31, 2014.

Comprehensive Income (Loss)

The Company does not have items of other comprehensive income (loss) for the three and six months ended June 30, 2015 or June 30, 2014; and therefore, comprehensive loss equals net loss for those periods.

Recently Issued Accounting Pronouncements

In April 2014, the Financial Accounting Standards Board (the “FASB”) issued guidance that changes the criteria for determining which disposals can be presented as discontinued operations and modifies related disclosure requirements. Under the new guidance, a discontinued operation is defined as a component or group of components that is disposed of or is classified as held for sale and represents a strategic shift that has or will have a major effect on an entity’s operations and financial results. The change is effective for fiscal years, and interim reporting periods within those years, beginning on or after December 15, 2014, which means the Company’s first quarter of 2015, with early adoption permitted. The guidance applies prospectively to new disposals and new classifications of disposal groups as held for sale after the effective date. The adoption of this new guidance did not affect the Company’s consolidated financial position, results of operations or cash flows.

In May 2014, the FASB issued Accounting Standards Update (“ASU”) 2014-09, “

Revenue from Contracts with Customers

(Accounting Standards Codification (“ASC”) Topic 606).” In July 2015, the FASB deferred the effective date of ASU 2014-09 by one year. The core principle

of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps:

Step 1: Identify the contract(s) with a customer.

Step 2: Identify the performance obligation in the contract.

Step 3: Determine the transaction price.

Step 4: Allocate the transaction price to the performance obligations in the contract.

Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation.

For public entities, ASU 2014-09 is now effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. Early adoption is permitted as of January 1, 2017. Entities have the option of applying either a full retrospective approach or a modified approach to adopt the guidance in ASU 2014-09. The Company is evaluating the potential impact of adoption of this ASU on its consolidated financial statements.

In August 2014, the FASB issued ASU 2014-15,

Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern

(“ASU 2014-15”). This pronouncement provides additional guidance surrounding the disclosure of going concern uncertainties in the financial statements and implementing requirements for management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date the financial statements are issued. The Company will adopt this guidance as of January 1, 2016. The Company does not anticipate that the adoption of this guidance will result in additional disclosures; however, management will begin performing the periodic assessments required by ASU 2014-15 on its effective date.

Note 3 - Acquisitions

6 Months Ended

Jun. 30, 2015

Notes to Financial Statements

Business Combination Disclosure [Text Block]

3.	Acquisitions

Paloma and VasculoMedics Acquisitions

On March 3, 2014, the Company entered into an agreement and plan of merger with Paloma Acquisition, Inc., Paloma Pharmaceuticals, Inc. (“Paloma”) and David Sherris, Ph.D., as founding stockholder and holder representative, pursuant to which the Company agreed to acquire by virtue of a merger all of the outstanding capital stock of Paloma, with Paloma becoming a wholly owned subsidiary of the Company. On March 28, 2014, the merger with Paloma was effected and the Company issued an aggregate of 2,500,000 shares of common stock to the holders of Paloma’s common stock and its derivative securities, which included the assumption of promissory notes of Paloma in the aggregate amount (including both principal amount and accrued interest) of approximately $1,151,725, to be paid on the first anniversary of the closing date of the Paloma merger. On August 5, 2014, the Company repaid in full the then-outstanding balance, including accrued interest, of the Paloma assumed promissory notes, totaling $1,331,007. The notes were terminated upon their prepayment and there were no early termination fees.

Also on March 3, 2014, the Company entered into an agreement and plan of merger with VasculoMedics Acquisition, Inc., VasculoMedics, Inc. (“VasculoMedics”) and David Sherris, Ph.D. pursuant to which the Company agreed to acquire by virtue of a merger all of the outstanding capital stock of VasculoMedics, with VasculoMedics becoming a wholly owned subsidiary of the Company. The VasculoMedics merger was concurrently closed with and as a condition to the closing of the Paloma merger on March 28, 2014 and the Company issued an aggregate of 220,000 shares of common stock to the VasculoMedics stockholders.

The acquisitions of Paloma and VasculoMedics were additional steps in the implementation of the Company’s plan to position itself as a specialty biopharmaceutical company. The total purchase consideration for the Paloma and VasculoMedics acquisitions was $6,800,000.

The transaction has been accounted for using the acquisition method of accounting which requires that assets acquired and liabilities assumed be recognized at their fair values as of the acquisition date. The valuation technique utilized to value the intangible assets was the cost approach. The following table summarizes the assets acquired and liabilities assumed as of the acquisition date:

	March 3, 2014
Intangibles assets	$	6,449,628
Prepaid expenses and other current assets		23,642
Property, plant and equipment		58,123
Goodwill		3,829,858
Accrued liabilities		(135,000	)
Notes payable and accrued interest		(1,151,725	)
Deferred tax liability		(2,274,526	)
Net assets acquired	$	6,800,000

Pro Forma Financial Information (Unaudited)

The following pro forma financial information reflects the consolidated results of operations of the Company as if the acquisitions of Paloma and VasculoMedics had taken place on January 1, 2013. The pro forma information includes acquisition and integration expenses. The pro forma financial information is not necessarily indicative of the results of operations as they would have been had the transactions been effected on the assumed date.

	Six Months Ended June 30, 2014
Net revenues	$	0
Net loss		(6,142,501	)
Basic and diluted loss per share	$	(0.54	)

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1500-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1524-128463

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4922-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4934-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4926-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

+ Details

Note 4 - Prepaid Expenses, Deposits and Other Assets

6 Months Ended

Jun. 30, 2015

Notes to Financial Statements

Prepaid Expenses, Deposits and Other Assets [Text Block]

4.	Prepaid Expenses, Deposits and Other Assets

In July 2013, the Company entered into an agreement with Maxim Group LLC (“Maxim”) to provide general financial advisory and investment banking services to the Company for three years on a non-exclusive basis. Under this agreement, the Company issued Maxim 210,250 shares of the Company’s common stock. These shares were valued at $15.00 per share, which was the closing price of the common stock on the date of the agreement, for a total expense of $3,153,750. This expense is being recognized ratably over the life of the three-year term of the agreement at $262,813 per quarter. As of June 30, 2015, $1,051,249 remained in prepaid expenses, deposits and other assets related to the Maxim agreement on the condensed consolidated balance sheets.

Note 5 - Property and Equipment, Net

6 Months Ended

Jun. 30, 2015

Notes to Financial Statements

Property, Plant and Equipment Disclosure [Text Block]

5 .	Property and Equipment, N et

Property and equipment were as follows:

	June 30, 2015			December 31, 2014

Computing equipment and office machines	$	38,785		$	16,072
Furniture and fixtures		35,196			32,945
Leasehold improvements		5,157			60,017
		79,138			109,034
Less accumulated depreciation		(10,356	)		(6,719	)
Property and equipment, net	$	68,782		$	102,315

For the three and six months ended June 30, 2015, depreciation was $6,198 and $12,482, respectively. For the three and six months ended June 30, 2014, depreciation was $2,555 and $7,066, respectively. During the three and six months ended June 30, 2015 and 2014, the Company disposed of certain property and equipment, resulting in a loss on disposal of $49,278 and $6,056, respectively, which is included within general and administrative expenses on the condensed consolidated statements of operations.

Note 6 - Intangible Assets, Net

6 Months Ended

Jun. 30, 2015

Notes to Financial Statements

Intangible Assets Disclosure [Text Block]

6 .	Inta n gible Assets, Net

Intangible assets were as follows:

	June 30 , 2015						December 31, 2014
	Gross Carrying Amount		Accumulated Amortization		Intangible Assets, net		Gross Carrying Amount		Accumulated Amortization		Intangible Assets, net
In-process research and development costs (IPR&D)	$	6,449,628	$	0	$	6,449,628	$	6,449,628	$	0	$	6,449,628

For the three months and six months ended June 30, 2014, the Company recorded amortization expense on finite lived intangible assets of $321,186 and $508,005 within depreciation and amortization on the condensed consolidated statements of operations. Such amortization expense related to intangible assets acquired in the Company’s acquisition of Canterbury Laboratories LLC and Hygeia Therapeutics, Inc., which the Company abandoned and wrote-off in the fourth quarter of 2014. See Note 6 to the Company’s consolidated financial statements for the year ended December 31, 2014 included in the Company’s annual report on Form 10-K for the year ended December 31, 2014.

The Company performed its review for impairment of its in-process research and development (“IPR&D”) intangible asset as prescribed in ASC 350 and also following guidance from “AICPA’s Accounting & Valuation Guide: Assets Acquired to Be Used in R&D Activities,” and has determined that there has been no impairment to this asset as of June 30, 2015

Note 7 - Goodwill	6 Months Ended
Note 7 - Goodwill	Jun. 30, 2015
Notes to Financial Statements
Goodwill Disclosure [Text Block]	7. Goodwill The Company’s goodwill as of June 30, 2015 was $12,055,991. Goodwill is the excess of the cost of an acquired entity over the net amounts assigned to tangible and intangible assets acquired and liabilities assumed. The Company applies ASC 350 “ Goodwill and Other Intangible Assets ,” which requires testing goodwill for impairment on an annual basis. The Company assesses goodwill for impairment as part of its annual reporting process in the fourth quarter. In between valuations, the Company conducts additional tests if circumstances indicate a need for testing. An annual impairment review was most recently completed on December 31, 2014. As of the December 31, 2014 impairment review, there was no impairment loss associated with recorded goodwill as the estimated fair value exceeded the carrying amount. The fair value of the reporting unit as of December 31, 2014, for the purpose of assessing the impairment of goodwill, was determined based on a primary analysis method, which provided a market capitalization of $66.1 million as of December 31, 2014. The Company determined that the fair value of its businesses for accounting purposes was equal to its market capitalization of approximately $66.1 million, which the Company then compared to its stockholders’ equity of $38.2 million, noting that fair value exceeded the carrying value, and therefore, indicated no impairment of goodwill. The Company considers certain triggering events when evaluating whether an interim impairment analysis is warranted. Among these would be a significant long-term decrease in the market capitalization of the Company based on events specific to the Company’s operations. Although the Company’s market capitalization has decreased significantly during the past several months, as of June 30, 2015, the Company’s market capitalization approximated its stockholders’ equity of $31.8 million. Management concluded that given the short time period of the noted decrease, the inactive trading activity in the Company’s stock and the lack of a specific event triggering the decrease, there has not been a sustained decrease in the Company’s share price; and therefore, no triggering event has occurred during the first six months of 2015. If the Company’s recent stock price decline continues or if the Company’s market capitalization does not increase, it is possible that the Company’s goodwill might experience an impairment at the next annual impairment review anticipated during fourth quarter of 2015 or earlier if management determines that a triggering event has occurred.

Note 8 - Other Accrued Liabilities

6 Months Ended

Jun. 30, 2015

Notes to Financial Statements

Other Liabilities Disclosure [Text Block]

8 .	Other Accrued Liabilities

Other accrued liabilities consisted of the following:

	June 30 , 2015		December 31, 2014
Payroll related	$	414,676	$	741,032
Former employee severance		685,824		0
Professional fees		98,282		217,663
Board fees		55,938		55,000
Rent liability for facilities no longer occupied		808,418		808,418
Other		167,113		99,180
	$	2,230,251	$	1,921,293

Note 9 - Stockholder's Equity

6 Months Ended

Jun. 30, 2015

Notes to Financial Statements

Stockholders' Equity Note Disclosure [Text Block]

9 .	Stockholder’s Equity

Common Stock

During the three and six months ended June 30, 2015, the Company did not issue, purchase or retire any shares of its common stock.

Warrants

During the three months and six months ended June 30, 2015, the Company did not grant any warrants to purchase shares of its common stock and no warrants were exercised. During the three and six months ended June 30, 2015, warrants to purchase an aggregate of 6,500 and 15,000 shares of common stock expired unexercised.

In December 2014, the Company issued to its investor relations firm a warrant to purchase 250,000 shares of common stock at an exercise price of $3.75 in consideration for investor relations services for one year, commencing December 15, 2014 and ending December 14, 2015. This warrant has a five-year term and was immediately vested and exercisable as of the date of grant, resulting in Black-Scholes warrant value of $517,576, of which $129,147 and $258,577 was expensed in general and administrative expenses during the three months and six months ended June 30, 2015.

Warrants to purchase an aggregate of 4,808,766 shares of the Company’s common stock were outstanding and exercisable as of June 30, 2015 with per share exercise prices ranging from $2.00 to $200.00 and a weighted average exercise price of $8.32 per share.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

+ Details

Note 10 - Stock-Based Compensation

6 Months Ended

Jun. 30, 2015

Notes to Financial Statements

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

10 .	Stock-Based Compensation

During the three and six months ended June 30, 2015, the Company granted options to purchase 6,650 shares of its common stock and no options were exercised. During the three and six months ended June 30, 2015, options to purchase an aggregate of 418,649 and 556,624 shares of common stock were cancelled or expired unexercised. Options to purchase an aggregate of 3,098,273 shares of common stock were outstanding as of June 30, 2015, and options to purchase an aggregate of 1,526,516 shares of common stock were exercisable as of June 30, 2015.

During the three months ended June 30, 2015, the Company amended certain options to extend the vesting and the post-termination exercise period, resulting in additional stock-based compensation expense of $45,953 in the three and six months ended June 30, 2015.

On March 5, 2015, the Company’s Board of Directors approved the RestorGenex Corporation 2015 Equity Incentive Plan (the “2015 Equity Plan”), and on June 17, 2015, the Company’s stockholders approved the 2015 Equity Plan. The 2015 Equity Plan allows for the issuance of up to a maximum of 2,500,000 shares of common stock in connection with the grant of stock-based awards, including stock options, restricted stock, restricted stock units, stock appreciation rights and other types of awards as deemed appropriate. As of June 30, 2015, options to purchase 6,650 shares of common stock were outstanding and 2,493,350 shares of common stock remained available for grant under the 2015 Equity Plan.

Options are granted with per share exercise prices equal to the per share fair value of the common stock on the date of grant. The Company recognizes the fair value of stock-based awards granted in exchange for employee and non-employee services as a cost of those services. The Company recognizes stock-based compensation expense for option awards on a straight-line basis over the vesting period.

The following table summarizes the stock-based compensation expense for employees and non-employees recognized in the Company’s condensed consolidated statements of operations for the periods indicated:

	Three Months Ended June 30 ,				Six Months Ended June 30 ,
	2015		2014		2015		2014
Research and development	$	152,645	$	32,825	$	384,170	$	32,825
General and administrative		374,544		108,490		748,446		258,375
Total stock-based compensation expense	$	527,189	$	141,315	$	1,132,616	$	291,200

As of June 30, 2015, the Company had $3,637,492 of total unrecognized compensation cost related to unvested stock-based compensation arrangements granted to employees. That cost is expected to be recognized over a weighted-average service period of 1.91 years.

Note 11 - Basic and Diluted Net Loss Per Share

6 Months Ended

Jun. 30, 2015

Notes to Financial Statements

Earnings Per Share [Text Block]

11 .	Basic and Diluted Net Loss Per Share

Basic net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share is computed similar to basic net loss per share except that the denominator is increased to include the number of additional shares of common stock that would have been outstanding if all of the Company’s potential shares, warrants and stock options had been issued and if the additional shares are dilutive.

Because of their anti-dilutive effect, all stock options and warrants for the three and six months ended June 30, 2015 and 2014, respectively, have been excluded from the calculation of diluted net loss per share.

	Three Months Ended June 30,						Six Months Ended June 30,
	2015			2014			2015			2014
Basic and dilutive numerator:
Net loss, as reported	$	(3,969,322	)	$	(4,455,232	)	$	(7,485,738	)	$	(5,835,407	)
Denominator:
Weighted-average shares outstanding		18,614,968			12,867,845			18,614,968			9,483,395
Net loss per share - basic and diluted	$	(0.21	)	$	(0.35	)	$	(0.40	)	$	(0.62	)

Note 12 - Commitments and Contingencies

6 Months Ended

Jun. 30, 2015

Notes to Financial Statements

Commitments and Contingencies Disclosure [Text Block]

. Commitments and Contingencies

Office Space Rental

On September 4, 2014, the Company entered into a lease agreement for office space totaling approximately 2,900 square feet in Buffalo Grove, Illinois and relocated its corporate headquarters to this facility in the third quarter of 2014. The term of the lease commenced on September 15, 2014 and will continue through February 28, 2018. The Company has an option to renew the lease for one renewal term of three years. Under the lease agreement, the first five months were rent free and then the base rent is approximately $6,000 per month through February 28, 2016 for a total of approximately $72,000 per year. The base rent will increase to approximately $6,100 per month for the first year thereafter and $6,200 per month for the second year thereafter.

The Company’s contractual obligations with respect to rental commitments as of June 30, 2015 were as follows:

	Rental Commitments
Payments due by period:
One year	$	72,203
Two years		73,638
Three years		49,729
Thereafter		—
Total	$	195,570

Purchase Obligations

As of June 30, 2015, the Company had future purchase obligation commitments for $2,149,002 in regards to the preclinical development of RES-529 and RES-440.

Litigation

From time to time, the Company is subject to various pending or threatened legal actions and proceedings, including those that arise in the ordinary course of its business, which may include employment matters, breach of contract disputes and stockholder litigation. Such actions and proceedings are subject to many uncertainties and to outcomes that are not predictable with assurance and that may not be known for extended periods of time. The Company records a liability in its condensed consolidated financial statements for costs related to claims, including future legal costs, settlements and judgments, where the Company has assessed that a loss is probable and an amount can be reasonably estimated. If the reasonable estimate of a probable loss is a range, the Company records the most probable estimate of the loss or the minimum amount when no amount within the range is a better estimate than any other amount. The Company discloses a contingent liability even if the liability is not probable or the amount is not estimable, or both, if there is a reasonable possibility that a material loss may have been incurred. In the opinion of management, as of June 30, 2015, the amount of liability, if any, with respect to these matters, individually or in the aggregate, will not materially affect the Company’s consolidated results of operations, financial position or cash flows.

On August 7, 2014, a complaint was filed in the Superior Court of Los Angeles County, California by Paul Feller, the Company’s former Chief Executive Officer under the caption

Paul Feller v. RestorGenex Corporation, Pro Sports & Entertainment, Inc., ProElite, Inc. and Stratus Media Group, GmbH

(Case No. BC553996). The complaint asserts various causes of action, including, among other things, promissory fraud, negligent misrepresentation, breach of contract, breach of employment agreement, breach of the covenant of good faith and fair dealing, violations of the California Labor Code and common counts. The plaintiff is seeking, among other things, compensatory damages in an undetermined amount, punitive damages, accrued interest and an award of attorneys’ fees and costs. On December 30, 2014, the Company filed a petition to compel arbitration and a motion to stay the action. On April 1, 2015, the plaintiff filed a petition in opposition to the Company’s petition to compel arbitration and a motion to stay the action. After a hearing for the petition and motion on April 14, 2015, the Court granted the Company’s petition to compel arbitration and a motion to stay the action. A status conference is scheduled for January 14, 2016. The Company believes this action is without merit and intends to defend the action vigorously. Because this lawsuit is in an early stage, the Company does not believe a loss is probable, and is unable to predict the outcome of the lawsuit and the possible loss or range of loss, if any, associated with its resolution or any potential effect the lawsuit may have on the Company’s financial position, results of operations or cash flows. Depending on the outcome or resolution of this lawsuit, it could have a material effect on the Company’s financial position, results of operations or cash flows.

Note 13 - Investment in Or-Genix	6 Months Ended
Note 13 - Investment in Or-Genix	Jun. 30, 2015
Notes to Financial Statements
Investment [Text Block]	13. Investment in Or-Genix In April 2015, the Company entered into several agreements with Or-Genix Therapeutics, Inc. (“Or-Genix”), pursuant to which the Company transferred certain of its non-focus technology rights to Or-Genix in exchange for a 19.9% ownership interest in Or-Genix, representing 2,484,395 shares of the common stock of Or-Genix, and purchased $250,000 in perpetual non-redeemable preferred stock which is included in other assets as of June 30, 2015. The rights the Company transferred include exclusive rights to a compound formerly known as “RES-102,” which is a “soft” estrogen potentially to be developed for the treatment of aging skin fragility/thinning and vulvo-vaginal atrophy, and exclusive rights to a compound formerly known as “RES-214,” a non-prescription cosmeceutical product under development by a sublicensee. The Company previously licensed these rights from Yale University and as part of this transaction assigned those license agreements to Or-Genix. The Company also assigned its rights under a sublicense agreement with Ferndale Pharma Group, Inc. for the formulation, manufacture, sale and marketing of RES-214. As the rights exchanged for the common stock investment had a recorded value of zero as of the transaction date, and as the common stock transaction was a non-monetary exchange, no value was assigned to the common stock portion of the Company’s Or-Genix investment and no gain or loss was recognized as a result of the transaction. Or-Genix is founded and owned primarily by Yael Schwartz, Ph.D., a former member of the Company’s Board of Directors and former Executive Vice President, Preclinical Development. The transfer of these technology rights to Or-Genix was executed since the Company is focusing its development efforts and resources on its other technologies. The Company does not control nor exercise significant influence over Or-Genix.

Note 14 - Former Employee Severance Expense	6 Months Ended
Note 14 - Former Employee Severance Expense	Jun. 30, 2015
Notes to Financial Statements
Former Employee Severance Expense [Text Block]	14. Former Employee Severance Expense On April 30, 2015, the Company entered into resignation agreements with the Company’s former Executive Vice President Preclinical Development and former Vice President of Pharmaceutical Sciences. As part of these resignation agreements, the Company modified their stock option agreements to provide for continued vesting until June 30, 2015 and to extend the post-termination exercise period from 90 days to one year, resulting in a minimal amount of additional stock-based compensation expense. On June 19, 2015, the Company entered into a resignation agreement with the Company’s former Chief Scientific Officer. Costs associated with the resignation agreements, primarily severance-related charges, are reflected in the former employee severance expense section in the condensed consolidated statement of operations for the three months and six months ended June 30, 2015. $685,824 related to these charges was included in other accrued liabilities as of June 30, 2015.

Significant Accounting Policies (Policies)	6 Months Ended
Significant Accounting Policies (Policies)	Jun. 30, 2015
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The unaudited financial statements presented in this report represent the consolidation of RestorGenex Corporation and its consolidated subsidiaries. The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) applicable to interim financial statements. Accordingly, certain information related to significant accounting policies and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) have been condensed or omitted. These unaudited condensed consolidated financial statements reflect, in the opinion of management, all material adjustments (which include only normally recurring adjustments) necessary to fairly state, in all material respects, the Company’s financial position, results of operations and cash flows for the periods presented. Operating results for interim periods are not necessarily indicative of the results that can be expected for any subsequent interim period or for a full year. These interim financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto included in its annual report on Form 10-K for the year ended December 31, 2014. On June 18, 2015, the Company changed its state of incorporation from the State of Nevada to the State of Delaware.
Reclassification, Policy [Policy Text Block]	Correction of Prior Period Misstatements In the fourth quarter of 2014, the Company recorded certain adjustments for misstatements related to prior 2014 interim and prior annual periods that had been deemed immaterial. See Note 2 to the Company’s consolidated financial statements for the year ended December 31, 2014, included in the Company’s annual report on Form 10-K for the year ended December 31, 2014, for further information as to the nature of the adjustments recorded in the fourth quarter of 2014. In the prior year presentation of research and development expenses for the three months ended June 30, 2014, the Company presented expenses of $403,413. Such amount included $169,332 of general and administrative expenses for the three month period ended June 30, 2014, which was included in research and development expenses in the period as a classification offset to the inclusion of $169,332 of research and development expenses in general and administrative expenses for the three month period ended March 31, 2014. The Company did not separately present research and development expenses in its condensed consolidated statements of operations for the three months ended March 31, 2014 as presented in the prior year. The inclusion of this $169,332 classification offset in the prior period presentation of research and development expenses for the three months ended June 30, 2014 was not appropriate, and represents an immaterial misstatement in the prior year. The prior year presentation of research and development expenses for the six month period ended June 30, 2014 was correct as presented. In the current period presentation of the condensed consolidated statements of operations for the three months ended June 30, 2014, this item has been corrected by decreasing research and development expenses and increasing general and administrative expenses by $169,332. $2,706,105 of expense recognized in the three and six months ended June 30, 2014 condensed consolidated statements of operations from notes payable settlements was reclassified to “loss on settlement of notes payable – related parties” expenses for $1,829,562 and “loss on settlement of notes payable” expense for $876,543 in the current period condensed consolidated statements of operations presentation from “fair value of common stock exchanged for warrants and notes payable” expense in the prior period presentation. Furthermore, the presentation of these amounts in the current period presentation was moved to other expense from operating expenses reflecting the correction of an immaterial prior period misstatement related to the classification of losses on settlement of notes payable. Reclassifications Certain 2014 amounts were reclassified to conform to the manner of presentation in the current period. These reclassifications included: $286,774 and $573,548 of amortization expense recognized in the three and six months ended June 30, 2014 condensed consolidated statements of operations from amortizing the prepaid expense asset for general financial advisory and investment banking services described in Note 4 to these condensed consolidated financial statements was reclassified to “general and administrative” expense in the current period condensed consolidated statements of operations presentation from “depreciation and amortization” expense where it was presented in the prior year. In the condensed consolidated statements of cash flows, the same amount was reclassified within the “cash flows used in operating activities” section from “depreciation and amortization” in the prior period presentation to “prepaid expenses, deposits and other assets” in the current period presentation. $141,315 and $291,200 of expense recognized in the three and six months ended June 30, 2014 condensed consolidated statements of operations presentation from stock-based compensation and warrant expense described in Notes 9 and 10 to these condensed consolidated financial statements was reclassified to “general and administrative” ($108,490 and $258,375 for the three and six months ended June 30, 2014) and “research and development” ($32,825 for the three and six months ended June 30, 2014) in the current period condensed consolidated statements of operations presentation from “warrants, options and stock compensation” expense in the prior period presentation. In the condensed consolidated statements of cash flows, the same amount was reclassified within the “cash flows used in operating activities” section from “warrants, options and stock compensation” in the prior period presentation to “employee and director stock-based compensation – non-cash” in the amount of $291,200 in the current period presentation. $384,604 and $516,290 of legal and professional services expense recognized in the three and six months ended June 30, 2014 condensed consolidated statements of operations was reclassified to “general and administrative” expense in the current period condensed consolidated statements of operations presentation from “legal and professional services” expense in the prior period presentation. $186,470 and $238,129 of income tax benefit recognized in the three and six months ended June 30, 2014 was reclassified to benefit from income taxes in the current period condensed consolidated statements of operations from other (income) expense in the prior year presentation. In the condensed consolidated statements of cash flows within net cash (used in) operating activities, $1,285,493 from loss on settlement of issuing shares for liabilities in the prior year presentation was reclassified to loss on settlement of note payable in the amount of $876,543 and accounts payable and accrued liabilities in the amount of $408,950 in the current year presentation.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of the Company’s condensed consolidated financial statements in accordance with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company’s condensed consolidated financial statements and accompanying notes. Although these estimates are based on the Company’s knowledge of current events and actions that the Company may undertake in the future, actual results may differ from such estimates and assumptions.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company has no current tax provision due to its current and accumulated losses, which result in net operating loss carryforwards. The Company’s deferred tax liability relates to indefinite lived intangible assets. See Note 18 to the Company’s consolidated financial statements for the year ended December 31, 2014 included in the Company’s annual report on Form 10-K for the year ended December 31, 2014.
Comprehensive Income, Policy [Policy Text Block]	Comprehensive Income (Loss) The Company does not have items of other comprehensive income (loss) for the three and six months ended June 30, 2015 or June 30, 2014; and therefore, comprehensive loss equals net loss for those periods.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Pronouncements In April 2014, the Financial Accounting Standards Board (the “FASB”) issued guidance that changes the criteria for determining which disposals can be presented as discontinued operations and modifies related disclosure requirements. Under the new guidance, a discontinued operation is defined as a component or group of components that is disposed of or is classified as held for sale and represents a strategic shift that has or will have a major effect on an entity’s operations and financial results. The change is effective for fiscal years, and interim reporting periods within those years, beginning on or after December 15, 2014, which means the Company’s first quarter of 2015, with early adoption permitted. The guidance applies prospectively to new disposals and new classifications of disposal groups as held for sale after the effective date. The adoption of this new guidance did not affect the Company’s consolidated financial position, results of operations or cash flows. In May 2014, the FASB issued Accounting Standards Update (“ASU”) 2014-09, “ Revenue from Contracts with Customers (Accounting Standards Codification (“ASC”) Topic 606).” In July 2015, the FASB deferred the effective date of ASU 2014-09 by one year. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps: Step 1: Identify the contract(s) with a customer. Step 2: Identify the performance obligation in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. For public entities, ASU 2014-09 is now effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. Early adoption is permitted as of January 1, 2017. Entities have the option of applying either a full retrospective approach or a modified approach to adopt the guidance in ASU 2014-09. The Company is evaluating the potential impact of adoption of this ASU on its consolidated financial statements. In August 2014, the FASB issued ASU 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (“ASU 2014-15”). This pronouncement provides additional guidance surrounding the disclosure of going concern uncertainties in the financial statements and implementing requirements for management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date the financial statements are issued. The Company will adopt this guidance as of January 1, 2016. The Company does not anticipate that the adoption of this guidance will result in additional disclosures; however, management will begin performing the periodic assessments required by ASU 2014-15 on its effective date.

- Definition

Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.

+ References + Details

Note 3 - Acquisitions (Tables)

6 Months Ended

Jun. 30, 2015

Paloma and Vasculo Medics [Member]

Notes Tables

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]

	March 3, 2014
Intangibles assets	$	6,449,628
Prepaid expenses and other current assets		23,642
Property, plant and equipment		58,123
Goodwill		3,829,858
Accrued liabilities		(135,000	)
Notes payable and accrued interest		(1,151,725	)
Deferred tax liability		(2,274,526	)
Net assets acquired	$	6,800,000

Business Acquisition, Pro Forma Information [Table Text Block]

	Six Months Ended June 30, 2014
Net revenues	$	0
Net loss		(6,142,501	)
Basic and diluted loss per share	$	(0.54	)

Note 5 - Property and Equipment, Net (Tables)

6 Months Ended

Jun. 30, 2015

Notes Tables

Property, Plant and Equipment [Table Text Block]

	June 30, 2015			December 31, 2014

Computing equipment and office machines	$	38,785		$	16,072
Furniture and fixtures		35,196			32,945
Leasehold improvements		5,157			60,017
		79,138			109,034
Less accumulated depreciation		(10,356	)		(6,719	)
Property and equipment, net	$	68,782		$	102,315

Note 6 - Intangible Assets, Net (Tables)

6 Months Ended

Jun. 30, 2015

Notes Tables

Schedule of Finite-Lived Intangible Assets [Table Text Block]

	June 30 , 2015						December 31, 2014
	Gross Carrying Amount		Accumulated Amortization		Intangible Assets, net		Gross Carrying Amount		Accumulated Amortization		Intangible Assets, net
In-process research and development costs (IPR&D)	$	6,449,628	$	0	$	6,449,628	$	6,449,628	$	0	$	6,449,628

Note 8 - Other Accrued Liabilities (Tables)

6 Months Ended

Jun. 30, 2015

Notes Tables

Other Current Liabilities [Table Text Block]

	June 30 , 2015		December 31, 2014
Payroll related	$	414,676	$	741,032
Former employee severance		685,824		0
Professional fees		98,282		217,663
Board fees		55,938		55,000
Rent liability for facilities no longer occupied		808,418		808,418
Other		167,113		99,180
	$	2,230,251	$	1,921,293

Note 10 - Stock-Based Compensation (Tables)

6 Months Ended

Jun. 30, 2015

Notes Tables

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]

	Three Months Ended June 30 ,				Six Months Ended June 30 ,
	2015		2014		2015		2014
Research and development	$	152,645	$	32,825	$	384,170	$	32,825
General and administrative		374,544		108,490		748,446		258,375
Total stock-based compensation expense	$	527,189	$	141,315	$	1,132,616	$	291,200

Note 11 - Basic and Diluted Net Loss Per Share (Tables)

6 Months Ended

Jun. 30, 2015

Notes Tables

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	Three Months Ended June 30,						Six Months Ended June 30,
	2015			2014			2015			2014
Basic and dilutive numerator:
Net loss, as reported	$	(3,969,322	)	$	(4,455,232	)	$	(7,485,738	)	$	(5,835,407	)
Denominator:
Weighted-average shares outstanding		18,614,968			12,867,845			18,614,968			9,483,395
Net loss per share - basic and diluted	$	(0.21	)	$	(0.35	)	$	(0.40	)	$	(0.62	)

Note 12 - Commitments and Contingencies (Tables)

6 Months Ended

Jun. 30, 2015

Notes Tables

Schedule of Maturities of Contractual Obligations [Table Text Block]

	Rental Commitments
Payments due by period:
One year	$	72,203
Two years		73,638
Three years		49,729
Thereafter		—
Total	$	195,570

Note 1 - Description of Business (Details Textual)	Jun. 30, 2015
Number of Phase I Clinicial Trials Completed	2

Note 2 - Basis of Presentation and Significant Accounting Policies (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Research and Development Expense [Member]
Prior Period Reclassification Adjustment, Stock-Based Compensation and Warrant Expense		$ 32,825		$ 32,825
General and Administrative Expense [Member]
Prior Period Reclassification Adjustment, Stock-Based Compensation and Warrant Expense		108,490		258,375
Loss on Settlement of Note Payable [Member]
Prior Period Reclassification Adjustment, Loss on Settlement of Issuing Shares for Liabilities				876,543
Scenario, Previously Reported [Member]
Research and Development Expense		403,413
Accounts Payable and Accrued Liabilities [Member]
Prior Period Reclassification Adjustment, Loss on Settlement of Issuing Shares for Liabilities				408,950
Prior Period Reclassification Adjustment, Notes Payable Settlements	$ 2,706,105	2,706,105
Gains (Losses) on Extinguishment of Related Party Debt		(1,829,562)		(1,829,562)
Gain (Loss) on Settlement of Notes Payable		(876,543)		(876,543)
Prior Period Reclassification Adjustment, Stock-Based Compensation and Warrant Expense		141,315		291,200
Research and Development Expense	$ 1,115,796	266,906	$ 2,667,348	436,238
Prior Period Reclassification Adjustment Research and Development Expense		169,332
Prior Period Reclassification Adjustment Income Tax Benefit		186,470		238,129
Prior Period Reclassification Adjustment, Amortization of Prepaid Expense Asset		286,774		573,548
Prior Period Reclassification Adjustment, Employee and Director Stock-Based Compensation NonCash				291,200
Prior Period Reclassification Adjustment, Legal and Professional Services		$ 384,604		516,290
Prior Period Reclassification Adjustment, Loss on Settlement of Issuing Shares for Liabilities				$ 1,285,493

Note 3 - Acquisitions (Details Textual) - USD ($)	Aug. 05, 2014	Mar. 28, 2014
Paloma and Vasculo Medics [Member] \| Notes Payable, Other Payables [Member]
Long-term Debt Prepayment Penalties	$ 0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Long-term Debt and Accrued Interest		$ 1,151,725
Repayments of Assumed Debt and Accrued Interest	$ 1,331,007
Paloma and Vasculo Medics [Member]
Business Combination, Consideration Transferred		$ 6,800,000
Paloma [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares		2,500,000
Vasculo Medics [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares		220,000

Note 3 - Acquisitions - Summary of Assets Acquired and Liabilities Assumed (Details)	Mar. 03, 2014 USD ($)
Paloma and Vasculo Medics [Member]
Intangibles assets	$ 6,449,628
Prepaid expenses and other current assets	23,642
Property, plant and equipment	58,123
Goodwill	3,829,858
Accrued liabilities	(135,000)
Notes payable and accrued interest	(1,151,725)
Deferred tax liability	(2,274,526)
Net assets acquired	$ 6,800,000

Note 3 - Acquisitions - Pro Forma Information (Details) - Paloma and Vasculo Medics [Member]	6 Months Ended
	Jun. 30, 2014 USD ($) $ / shares
Net revenues	$ 0
Net loss	$ (6,142,501)
Basic and diluted loss per share (in dollars per share) \| $ / shares	$ (0.54)

Note 4 - Prepaid Expenses, Deposits and Other Assets (Details Textual) - USD ($)	1 Months Ended	3 Months Ended
	Jul. 31, 2013	Jun. 30, 2015	Dec. 31, 2014
Maxim Group LLC [Member]
Term of Agreement	3 years
Share-based Goods and Nonemployee Services Transaction, Shares Approved for Issuance	210,250
Share Price	$ 15
Share-based Goods and Nonemployee Services Transaction, Capitalized Cost	$ 3,153,750
Value of Shares of Common Stock Recognized Per Quarter		$ 262,813
Prepaid Expenses, Deposits, and Other Assets		1,051,249
Prepaid Expenses, Deposits, and Other Assets		$ 1,357,191	$ 2,286,930

Note 5 - Property and Equipment, Net (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property	$ 49,278	$ 6,056	$ 49,278	$ 6,056
Depreciation	$ 6,198	$ 2,555	$ 12,482	$ 7,066

Note 5 - Property and Equipment, Net - Property and Equipment (Details) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Computer Equipment and Office Machines [Member]
Property and equipment, gross	$ 38,785	$ 16,072
Furniture and Fixtures [Member]
Property and equipment, gross	35,196	32,945
Leasehold Improvements [Member]
Property and equipment, gross	5,157	60,017
Property and equipment, gross	79,138	109,034
Less accumulated depreciation	(10,356)	(6,719)
Property and equipment	$ 68,782	$ 102,315

Note 6 - Intangible Assets, Net (Details Textual) - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2014
Amortization of Intangible Assets	$ 321,186	$ 508,005

Note 6 - Intangible Assets, Net - Intangible Assets, Net (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
In Process Research and Development [Member]
Gross Carrying Amount	$ 6,449,628	$ 6,449,628
Accumulated Amortization	0	0
Intangible Assets, Net	$ 6,449,628	$ 6,449,628

Note 7 - Goodwill (Details Textual) - USD ($)	12 Months Ended
Note 7 - Goodwill (Details Textual) - USD ($)	Dec. 31, 2014	Jun. 30, 2015
Goodwill, Impairment Loss	$ 0
Goodwill	12,055,991	$ 12,055,991
Market Capitalization	66,100,000
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	$ 38,165,625	$ 31,811,987

Note 8 - Other Accrued Liabilities - Other Accrued Expenses and Other Liabilities (Details) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Payroll related	$ 414,676	$ 741,032
Former employee severance	685,824	0
Professional fees	98,282	217,663
Board fees	55,938	55,000
Rent liability for facilities no longer occupied	808,418	808,418
Other	167,113	99,180
	$ 2,230,251	$ 1,921,293

Note 9 - Stockholder's Equity (Details Textual) - USD ($)	1 Months Ended	3 Months Ended	6 Months Ended
	Dec. 31, 2014	Jun. 30, 2015	Jun. 30, 2015
Common Stock Warrants [Member] \| Investor Relations Firm [Member] \| General and Administrative Expense [Member]
Warrant Expense		$ 129,147	$ 258,577
Common Stock Warrants [Member] \| Investor Relations Firm [Member]
Warrants and Rights Outstanding		$ 517,576	$ 517,576
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	250,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 3.75
Term of Agreement with Counterparty	1 year
Class of Warrant or Right, Term	5 years
Common Stock Warrants [Member]
Class of Warrant or Right Exercised Number		0	0
Class of Warrant or Right, Granted During Period		0	0
Class of Warrant or Right Expired Unexercised		6,500	15,000
Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 2	$ 2
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 200	$ 200
Stock Issued During Period, Shares, New Issues		0	0
Stock Repurchased and Retired During Period, Shares		0	0
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		4,808,766	4,808,766
Class of Warrant or Right, Weighted Average Exercise Price			$ 8.32

Note 10 - Stock-Based Compensation (Details Textual) - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2015	Mar. 05, 2015
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	0	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	6,650	6,650
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period	418,649	556,624
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	3,098,273	3,098,273
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	1,526,516	1,526,516
Restorgenex Corporation 2015 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized			2,500,000
Additional Allocated Share-based Compensation Expense	$ 45,953	$ 45,953
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	2,493,350	2,493,350
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	$ 3,637,492	$ 3,637,492
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition		1 year 332 days

Note 10 - Stock-Based Compensation - Summary of Stock Option Compensation Expense (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Research and Development Expense [Member]
Stock-based compensation expense	$ 152,645	$ 32,825	$ 384,170	$ 32,825
General and Administrative Expense [Member]
Stock-based compensation expense	374,544	108,490	748,446	258,375
Stock-based compensation expense	$ 527,189	$ 141,315	$ 1,132,616	$ 291,200

Note 11 - Basic and Diluted Net Loss Per Share - Summary of Basic and Diluted Net Loss Per Share (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Basic and dilutive numerator:
Net loss, as reported	$ (3,969,322)	$ (4,455,232)	$ (7,485,738)	$ (5,835,407)
Denominator:
Weighted-average shares outstanding (in shares)	18,614,968	12,867,845	18,614,968	9,483,395
Net loss per share - basic and diluted (in dollars per share)	$ (0.21)	$ (0.35)	$ (0.40)	$ (0.62)

Note 12 - Commitments and Contingencies (Details Textual)		6 Months Ended
	Sep. 04, 2014 USD ($) ft²	Jun. 30, 2015 USD ($)
Buffalo Grove [Member] \| Long Term Operating Lease Agreement [Member] \| Building [Member]
Area of Real Estate Property \| ft²	2,900
Lessee Leasing Arrangements Operating Leases Number of Extension Options	1
Lessee Leasing Arrangements, Operating Leases, Renewal Term	3 years
Operating Leases, Number of Months from Lease Inception that Monthly Rent is Not Required to Be Paid	5
Operating Leases Monthly Rent Expense	$ 6,000
Operating Leases Annual Rent Expense	72,000
Operating Leases Annual Increase in Rent Expense for First Year	6,100
Operating Leases Annual Increase in Rent Expense For Second Year and Thereafter	$ 6,200
Long-term Purchase Commitment, Amount		$ 2,149,002

Note 12 - Commitments and Contingencies - Contractual Obligations (Details)	Jun. 30, 2015 USD ($)
Payments due by period:
One year	$ 72,203
Two years	73,638
Three years	49,729
Total	$ 195,570

Note 13 - Investment in Or-Genix (Details Textual) - USD ($)		6 Months Ended
	Apr. 30, 2015	Jun. 30, 2015	Jun. 30, 2014
Or Genix Therapeutics Inc [Member]
Cost Method Ownership Percentage	19.90%
Investment in Common Stock Shares	2,484,395
Payments to Acquire Investments	$ 250,000
Payments to Acquire Investments		$ 250,000

Note 14 - Former Employee Severance Expense (Details Textual) - USD ($)		4 Months Ended
	Apr. 30, 2015	Apr. 29, 2015	Jun. 30, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	1 year	90 days
Supplemental Unemployment Benefits, Severance Benefits			$ 685,824	$ 0